Voluntary serious illness revealed, stop Covid vaccine test

Jakarta, CNBC Indonesia – AstraZeneca has stopped the trials of the third phase of the Covid-19 vaccine worldwide. In fact, the candidate vaccine that they developed with the University of Oxford can be considered the most important compared to others.

In the report STAT News, the volunteers were revealed to have side effects. Namely, neurological symptoms consistent with a rare but serious inflammatory spinal disorder.

“It’s also called transverse myelitis (transverse myelitis),” AstraZeneca CEO Pascal Soriot said in an investor conference on Wednesday (9/9/2020), quoted on Thursday (10/9/2020).

But he said the diagnosis had not been confirmed. Currently, the volunteer identified as a woman from England is being treated in a hospital.

Photo: AstraZeneca CEO Pascal Soriot / doc.AstraZeneca AstraZeneca CEO Pascal Soriot / doctor AstraZeneca

He confirmed that the conditions of the volunteers had been reversed. “He will be released from the hospital on Wednesday (local time),” he said.

In fact, the clinical trial was also briefly stopped in July. One participant was also neurological.

But after further testing, the participant had been diagnosed with multiple sclerosis, which is not considered related to the vaccine treatment. Unfortunately, a company spokesperson, STAT said, declined to comment.

Neurology is a disorder of the nervous system. Transverse myelitis is an inflammation of a part of the spinal cord with a number of accompanying conditions, such as pain, numbness or numbness, weakness in the legs or arms, and disturbances in urination and defecation.

Previously, the company announced the temporary suspension of the final trial of the vaccine. Usually a clinical suspension like this occurs, but it is unclear how long AstraZeneca performed it.

“This interruption is a routine thing to do whenever potential unexplained disease (shows up) in one of the trials,” STAT wrote, citing an AstraZeneca spokesperson.

“While investigating, we maintain the integrity of the test,” the company said again, emphasizing that it was working quickly to minimize the impact of the test.

In the US, AstraZaneca’s final trial has been held since the end of August at 62 locations. Previously, 2/3 of the tests had been carried out in England, Brazil and South Africa.

(Head to head)